key: cord-0790858-ckg4cgx7 authors: Klug, M. E.; Lazareva, O.; Kirmes, K.; Rosenbaum, M.; Lukas, M.; Weidlich, S.; Spinner, C. D.; von Scheidt, M.; Gosetti, R.; Baumbach, J.; Ruland, J.; Condorelli, G.; Laugwitz, K.-L.; List, M.; Bernlochner, I.; Bongiovanni, D. title: Platelet expression and reactivity after BNT162b2 vaccine administration date: 2021-05-18 journal: nan DOI: 10.1101/2021.05.18.21257324 sha: 5409875fd3e5eb99211906303fd1f67fa5f2e60c doc_id: 790858 cord_uid: ckg4cgx7 SARS-CoV-2 infection induces a coagulopathy characterized by platelet activation and a hypercoagulable state with an increased incidence of cardiovascular events. The viral spike protein S has been reported to enhance thrombosis formation, stimulate platelets to release pro-coagulant factors and promote the formation of platelet-leukocyte aggregates even in absence of the virus. Although SARS-CoV-2 vaccines induce spike protein overexpression to trigger SARS-CoV-2-specific immune protection, thrombocyte activity has not been investigated in this context. Here, we provide the first phenotypic platelet characterization of healthy human subjects undergoing BNT162b2 vaccination. Using mass cytometry, we analyzed the expression of constitutive transmembrane receptors, adhesion proteins and platelet activation markers in 12 healthy donors before and at five different timepoints within four weeks after the first BNT162b2 administration. We measured platelet reactivity by stimulating thrombocyte activation with thrombin receptor-activating peptide (TRAP). Activation marker expression (P-Selectin, LAMP-3, LAMP-1, CD40L and PAC-1) did not change after vaccination. All investigated constitutive transmembrane proteins showed similar expressions over time. Platelet reactivity was not altered after BNT162b2 administration. Activation marker expression was significantly lower compared to an independent cohort of mild symptomatic COVID-19 patients analyzed with the same platform. This study reveals that BNT162b2 administration does not alter platelet protein expression and reactivity. isabell.bernlochner@tum.de . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257324 doi: medRxiv preprint Abstract SARS-CoV-2 infection induces a coagulopathy characterized by platelet activation and a hypercoagulable state with an increased incidence of cardiovascular events. The viral spike protein S has been reported to enhance thrombosis formation, stimulate platelets to release pro-coagulant factors and promote the formation of platelet-leukocyte aggregates even in absence of the virus. Although SARS-CoV-2 vaccines induce spike protein overexpression to trigger SARS-CoV-2-specific immune protection, thrombocyte activity has not been investigated in this context. Here, we provide the first phenotypic platelet characterization of healthy human subjects undergoing BNT162b2 vaccination. Using mass cytometry, we analyzed the expression of constitutive transmembrane receptors, adhesion proteins and platelet activation markers in 12 healthy donors before and at five different timepoints within four weeks after the first BNT162b2 administration. We measured platelet reactivity by stimulating thrombocyte activation with thrombin receptor-activating peptide (TRAP). Activation marker expression (P-Selectin, LAMP-3, LAMP-1, CD40L and PAC-1) did not change after vaccination. All investigated constitutive transmembrane proteins showed similar expressions over time. Platelet reactivity was not altered after BNT162b2 administration. Activation marker expression was significantly lower compared to an independent cohort of mild symptomatic COVID-19 patients analyzed with the same platform. This study reveals that BNT162b2 administration does not alter platelet protein expression and reactivity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Introduction SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) can lead to a hypercoagulable state with increased incidence of adverse cardiovascular events [1] [2] [3] [4] . Over the last months, several studies highlighted thrombocyte activation as a key feature of COVID-19 induced coagulopathy [5] [6] [7] . We recently described a dysregulation of platelet expression and reactivity even during mild COVID-19 disease characterized by an upregulation of activation markers as well as of the transmembrane proteins GPIIb/IIIa, GPIX and GPIa, which regulate platelet activation 8 . However, the pathophysiological mechanism responsible for COVID-19 induced coagulopathy and of the increased incidence of cardiovascular events remains unclear. A recent study reported that the SARS-CoV-2 spike protein S enhances thrombosis formation, stimulates human platelets to release pro-coagulant factors and promotes platelet-leukocyte aggregate formation even in absence of the virus 9 . This direct effect on platelets could explain the sustained platelet activation during COVID-19 and raises safety concerns regarding the newly developed vaccines. In fact, although SARS-CoV-2 vaccines induce spike protein overexpression to trigger SARS-CoV-2specific immune protection, thrombocyte activity has not been investigated in this context. Nevertheless, all vaccines available passed phase III trials 10-12 but the recently reported thrombotic events following vaccine administration, including BNT162b2, raised concerns worldwide 13, 14 . Moreover, an immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which mimics autoimmune heparin-induced thrombocytopenia, has been reported after ChAdOx1 vaccine administration 15 . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05. 18.21257324 doi: medRxiv preprint In this study, we performed the first phenotypic thrombocyte characterization in healthy donors undergoing BNT162b2 vaccine administration using mass cytometry by time of flight (CyTOF). We recruited 12 healthy donors undergoing vaccination with BNT162b2 without preexisting conditions or therapy. In all donors, the second dose of BNT162b2 was delivered 21 days after the first one. Blood samples were collected 1 day before vaccination (timepoint 0: TP0) and at 5 different timepoints after the first dose ( Figure 1A , supplemental figure 1): day 1-2 (timepoint 1: TP1); day 3-4 (timepoint 2: TP2); day 14 (timepoint 3: TP3); day 22 (one day after the second dose, timepoint 4: TP4) and day 28 (+7 days after the second dose, timepoint 5: TP5). Peripheral venous blood was collected from each donor and immediately processed to platelet-rich plasma and stained for CyTOF analysis as described previously 8, 16 . All participants gave written informed consent. The study was approved by the local ethics committee (approval number 4/21 S-KH) and complies to the Declaration of Helsinki. Briefly, two samples were prepared from each blood collection: one baseline sample CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257324 doi: medRxiv preprint anti-CD62P-161Dy, anti-CD63-150Nd, anti-CD69-162Dy, anti-CD107a-151Eu, anti-CD154-168Er, anti-PAC1-155Gd and anti-Par1-147Sm antibodies; see major resources table for antibody information). Samples were then prepared according to the Maxpar cell surface staining protocol as described previously 8 . For acquisition, cells were diluted to a final concentration of 10 3 platelets/µl in 10% EQ calibration beads in cell acquisition solution (CAS). All samples were prepared and measured by the same scientist. Throughout the study, all samples of one donor were measured at the same day to reduce batch effect. In total, 299,408 ± 1,364 events per sample were acquired at a rate of 200-350 events per second. After acquisition at the Helios CyTOF system (Fluidigm), samples were normalized, processed and pre-gated using the Cytobank™ software (www.cytobank.org, Beckman-Coulter, Brea, CA, USA) 17 . We performed computational analysis with Cytobank and statistical tests were performed on the transformed data using the scipy python package (version 1.6.3) 18 . Mann-Whitney U test for one-sided pair-wise comparison of different time points. Pvalues are reported uncorrected for multiple hypothesis testing on the account that no significant p-values were obtained. FlowSOM analysis was performed using the implementation in Cytobank. Gated, compensated, scaled and transformed files were used as input. 11 markers were used for clustering excluding activation markers, the extremely lowly expressed marker CD40 and the control marker CD3. Cells were assigned to a 10 × 10 self-. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257324 doi: medRxiv preprint organizing map before meta-clustering. FlowSOM analysis was run separately for each timepoint and condition using the same minimum spanning tree and seed with 10 000 events per sample. For each cluster, a P value was computed with the onesided Mann-Whitney U test (see supplemental table 4) . Protein expression level of the activation markers P-Selectin and LAMP-3 were compared with those of two independent cohorts analyzed previously with the same platform 8 : a group of eight patients with no pre-existing conditions requiring hospitalization due to symptomatic COVID-19 and a control group of eleven healthy donors tested negative for SARS-CoV-2 infection. All mass cytometry data and FlowSOM results have been made available at flowrepository.org 19 and can be accessed at repository ID FR-FCM-Z3XS. The scripts used in this analysis have been deposited at github.com and can be accessed at https://github.com/biomedbigdata/Platelet-activation-after-vaccine-administration. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257324 doi: medRxiv preprint To investigate platelet reactivity, we measured the activation marker expression after stimulation with TRAP. Protein expression rose after TRAP-stimulation similarly before and after vaccine administration ( Figure 1C ). The expression of constitutive transmembrane receptors and adhesion proteins after TRAP-stimulation did not differ before and after vaccination (supplemental table 3 ). The Overall, no significant differences were detected within clusters concerning activation marker expression. We compared protein expression levels before and after vaccination with two independent cohorts analyzed previously with the same platform 8 : COVID-19 symptomatic patients with no pre-existing condition requiring hospitalization and a healthy control group of donors tested negative for SARS-CoV-2 infection. Figure 2B provides an overview of P-Selectin and LAMP-3 expression. Expression levels of activation markers are comparable with those of healthy donors tested negative for COVID-19 and differ from COVID-19 patients. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We here provide the first mass cytometric analysis of protein expression after SARS-CoV-2 vaccination. A recent study suggested a direct effect on thrombocytes of the spike protein S, sought to be mediated through the ACE2 receptor 9 . Zang et al. reported that the spike protein alone (without presence of the virus) can dose-dependently enhance platelet aggregation, ATP release and dense granule secretion. Moreover, they reported that the spike protein induces GPIIb/IIIa activation and P-Selectin expression even in the absence of agonists 9 . In contrast to these findings, we observed that the expression level of the activated form of GPIIb/IIIa (PAC-1) as well as of other activation markers -including P-Selectin -does not change after the spike protein upregulation mediated by vaccination with BNT162b2 ( Figure 1A -B and supplemental figure S1). Of note, the expression profiles after vaccination differed from COVID-19 patients characterized by the same experimental pipeline and remained similar to an independent control cohort ( Figure 2B ). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 1 Platelet reactivity to physiological stimulus with TRAP was not altered after vaccination in contrast to the dysregulation observed during SARS-CoV-2 infection 8, 21 . Clustering analysis of non-stimulated platelets did not detect a phenotypic modification after vaccination, in contrast to the specific cluster activation observed previously during SARS-CoV-2 infection 8 . Hence, our study shows that the vaccination does not generally lead to platelet activation or dysfunctional reactivity. We acknowledge the limitations of our investigations: with our restricted sample size we did non aim to investigate the phenotypic expression of rare complications such as thromboembolic events or the presence of vaccine-induced immune thrombotic thrombocytopenia (VITT), that has been reported after ChAdOx1 administration 15, 22 . Moreover, we recruited donors undergoing vaccination only with BNT162b2 administration. While all vaccines induce protein spike S upregulation, they use different vectors. Thus, our findings cannot be directly translated to all available vaccines. Nevertheless, our study provides the first phenotypic characterization of platelets of healthy donors undergoing vaccination and provides additional biomolecular information. While a direct activity of spike protein S on platelets cannot be excluded, our data suggest that the spike protein S expression levels mediated by SARS-CoV-2 vaccines do not significantly alter platelet biology and function. In conclusion, mass cytometry of platelets after BNT162b2 vaccination did not detect any alteration of the platelet expression profile and platelet reactivity. Further studies are needed to characterize the pathophysiology of the rare thromboembolic events occurring after SARS-CoV-2 vaccination. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The authors declare that they have no conflict of interest, except CDS. Christoph Spinner reports grants, personal fees, non-financial support and other from AbbVie, grants, personal fees, non-financial support and other from Apeiron, personal fees from Formycon, grants, personal fees, non-financial support and other from Gilead Sciences, grants, personal fees and other from Eli Lilly, grants, personal fees, nonfinancial support and other from Janssen-Cilag, grants, personal fees, non-financial support and other from GSK/ViiV Healthcare, grants, personal fees, non-financial support and other from MSD, outside the submitted work. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) • SARS-CoV-2 spike protein enhances thrombosis formation, stimulates human platelets to release pro-coagulant factors and promotes platelet-leukocyte aggregate formation even in absence of the virus. • Platelet expression and reactivity after SARS-CoV-2 vaccination have not been investigated yet. • BNT162b2 vaccination does not alter the expression of platelet adhesion proteins and receptors • Vaccine-induced spike protein S upregulation does not lead to platelet activation or dysfunction. • Cluster analysis excluded a dysregulation of platelet subgroups. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257324 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257324 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence ST-Segment Elevation in Patients with Covid-19 -A Case Series COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year Platelet Gene Expression and Function in COVID-19 Patients Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19 SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19 Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Sorting and magnetic-based isolation of reticulated platelets from peripheral blood Web-Based Analysis and Publication of Flow Cytometry Experiments Array programming with NumPy FlowRepository: A resource of annotated flow cytometry datasets associated with peer-reviewed publications Platelet surface marker analysis by mass cytometry Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors